Private Equity

Lithium developer Stardust Power partners with a Pentagon-aligned group, a critical move to reduce foreign reliance and fuel the U.S. energy transition.

Hunt Energy Network acquires the massive Fort Duncan battery, boosting its Texas portfolio to 420MW and signaling an aggressive expansion in the booming ERCOT market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

The powertrain giant crushed market expectations with a 29% revenue surge in 2025, fueled by heavy-duty engines, while eyeing a global and green future.

After a massive divestiture, Brightstar Lottery slashes debt, rewards investors, and sets its sights on digital expansion in Italy and Brazil.

After an 8-year hiatus, Elizabeth Arden launches Eternal Aura. A look at the strategy combining a new star, wellness science, and heritage to reclaim its spot.

The former South Pole CEO's appointment signals a new era for PUR, focusing on high-integrity carbon markets and scaling holistic climate solutions.

The coffee giant posts impressive 2025 results amid high inflation, paving the way for its blockbuster acquisition by Keurig Dr Pepper. What's next?

Forvia reports a €2.1B net loss but shows improved operations and cash flow. Is this strategic pain a necessary step toward long-term gain?

Caidya appoints veteran Michael Clay as COO, leveraging his deep Asia-Pacific expertise to scale operations and solidify its position in the CRO market.

With key conferences ahead, Supernus Pharmaceuticals must prove its strategy can deliver growth in the competitive central nervous system drug landscape.

Shareholders approve a major private placement, injecting strategic capital from La Mancha to advance Brazil's controversial Volta Grande Gold Project.

The cannabis giant upsizes its credit facility by CAD $15M, signaling strong lender confidence and fueling its ambitious global expansion plans.

The fusion energy pioneer plans to go public via a SPAC merger, seeking capital to prove its unique technology and win the race for limitless clean power.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

A former hedge fund manager's stark video presentation warns that AI will permanently alter work and wealth. Are American workers prepared for what's next?